149 related articles for article (PubMed ID: 38395247)
1. Cancer risk in patients treated with denosumab compared with alendronate: A population-based cohort study.
Yahyavi SK; Holt R; Knudsen NK; Andreassen CH; Sejling C; Meddis A; Kjaer SK; Schwarz P; Jensen JB; Torp-Pedersen C; Juul A; Selmer C; Blomberg Jensen M
Bone; 2024 May; 182():117053. PubMed ID: 38395247
[TBL] [Abstract][Full Text] [Related]
2. Denosumab and Risk of Community-acquired Pneumonia: A Population-based Cohort Study.
Lyu H; Zhao S; Li J; Li X; Wang Y; Xie D; Zeng C; Lei G; Wei J; Li H
J Clin Endocrinol Metab; 2022 Jul; 107(8):e3366-e3373. PubMed ID: 35511602
[TBL] [Abstract][Full Text] [Related]
3. Comparison of anti-fracture effectiveness of zoledronate, ibandronate and alendronate versus denosumab in a registry-based cohort study.
Everts-Graber J; Bonel H; Lehmann D; Gahl B; Häuselmann H; Studer U; Ziswiler HR; Reichenbach S; Lehmann T
Osteoporos Int; 2023 Nov; 34(11):1961-1973. PubMed ID: 37493978
[TBL] [Abstract][Full Text] [Related]
4. Comparison of Risk of Osteoporotic Fracture in Denosumab vs Alendronate Treatment Within 3 Years of Initiation.
Pedersen AB; Heide-Jørgensen U; Sørensen HT; Prieto-Alhambra D; Ehrenstein V
JAMA Netw Open; 2019 Apr; 2(4):e192416. PubMed ID: 31002319
[TBL] [Abstract][Full Text] [Related]
5. Final results of the DAPS (Denosumab Adherence Preference Satisfaction) study: a 24-month, randomized, crossover comparison with alendronate in postmenopausal women.
Freemantle N; Satram-Hoang S; Tang ET; Kaur P; Macarios D; Siddhanti S; Borenstein J; Kendler DL;
Osteoporos Int; 2012 Jan; 23(1):317-26. PubMed ID: 21927922
[TBL] [Abstract][Full Text] [Related]
6. The effects of denosumab and alendronate on glucocorticoid-induced osteoporosis in patients with glomerular disease: A randomized, controlled trial.
Iseri K; Iyoda M; Watanabe M; Matsumoto K; Sanada D; Inoue T; Tachibana S; Shibata T
PLoS One; 2018; 13(3):e0193846. PubMed ID: 29543887
[TBL] [Abstract][Full Text] [Related]
7. Utilization patterns and factors associated with persistence of new users of anti-osteoporosis treatment in Denmark: a population-based cohort study.
Pedersen AB; Risbo N; Kafatos G; Neasham D; O'Kelly J; Ehrenstein V
Arch Osteoporos; 2023 Jan; 18(1):19. PubMed ID: 36629929
[TBL] [Abstract][Full Text] [Related]
8. Risk of venous thromboembolism among users of different anti-osteoporosis drugs: a population-based cohort analysis including over 200,000 participants from Spain and the UK.
Martín-Merino E; Petersen I; Hawley S; Álvarez-Gutierrez A; Khalid S; Llorente-Garcia A; Delmestri A; Javaid MK; Van Staa TP; Judge A; Cooper C; Prieto-Alhambra D
Osteoporos Int; 2018 Feb; 29(2):467-478. PubMed ID: 29199359
[TBL] [Abstract][Full Text] [Related]
9. Screening for the primary prevention of fragility fractures among adults aged 40 years and older in primary care: systematic reviews of the effects and acceptability of screening and treatment, and the accuracy of risk prediction tools.
Gates M; Pillay J; Nuspl M; Wingert A; Vandermeer B; Hartling L
Syst Rev; 2023 Mar; 12(1):51. PubMed ID: 36945065
[TBL] [Abstract][Full Text] [Related]
10. Adherence, preference, and satisfaction of postmenopausal women taking denosumab or alendronate.
Kendler DL; McClung MR; Freemantle N; Lillestol M; Moffett AH; Borenstein J; Satram-Hoang S; Yang YC; Kaur P; Macarios D; Siddhanti S;
Osteoporos Int; 2011 Jun; 22(6):1725-35. PubMed ID: 20827547
[TBL] [Abstract][Full Text] [Related]
11. One and two-year persistence with different anti-osteoporosis medications: a retrospective cohort study.
Reyes C; Tebe C; Martinez-Laguna D; Ali MS; Soria-Castro A; Carbonell C; Prieto-Alhambra D
Osteoporos Int; 2017 Oct; 28(10):2997-3004. PubMed ID: 28714038
[TBL] [Abstract][Full Text] [Related]
12. Effects of denosumab, alendronate, or denosumab following alendronate on bone turnover, calcium homeostasis, bone mass and bone strength in ovariectomized cynomolgus monkeys.
Kostenuik PJ; Smith SY; Samadfam R; Jolette J; Zhou L; Ominsky MS
J Bone Miner Res; 2015 Apr; 30(4):657-69. PubMed ID: 25369992
[TBL] [Abstract][Full Text] [Related]
13. The Efficacy of Alendronate Versus Denosumab on Major Osteoporotic Fracture Risk in Elderly Patients With Diabetes Mellitus: A Danish Retrospective Cohort Study.
Viggers R; Al-Mashhadi Z; Starup-Linde J; Vestergaard P
Front Endocrinol (Lausanne); 2021; 12():826997. PubMed ID: 35154013
[TBL] [Abstract][Full Text] [Related]
14. Denosumab compared with risedronate in postmenopausal women suboptimally adherent to alendronate therapy: efficacy and safety results from a randomized open-label study.
Roux C; Hofbauer LC; Ho PR; Wark JD; Zillikens MC; Fahrleitner-Pammer A; Hawkins F; Micaelo M; Minisola S; Papaioannou N; Stone M; Ferreira I; Siddhanti S; Wagman RB; Brown JP
Bone; 2014 Jan; 58():48-54. PubMed ID: 24141036
[TBL] [Abstract][Full Text] [Related]
15. The role of bone modifying agents for secondary osteoporosis prevention and pain control in post-menopausal osteopenic breast cancer patients undergoing adjuvant aromatase inhibitors.
Galvano A; Gristina V; Scaturro D; Bazan Russo TD; Tomasello S; Vitagliani F; Carità F; La Mantia M; Fulfaro F; Bazan V; Mauro GL; Russo A
Front Endocrinol (Lausanne); 2023; 14():1297950. PubMed ID: 38075057
[TBL] [Abstract][Full Text] [Related]
16. Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Jakob T; Tesfamariam YM; Macherey S; Kuhr K; Adams A; Monsef I; Heidenreich A; Skoetz N
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013020. PubMed ID: 33270906
[TBL] [Abstract][Full Text] [Related]
17. Denosumab: a review of its use in the treatment of postmenopausal osteoporosis.
Moen MD; Keam SJ
Drugs Aging; 2011 Jan; 28(1):63-82. PubMed ID: 21174488
[TBL] [Abstract][Full Text] [Related]
18. Persistance and Compliance with Osteroporosis Therapies Among Women in a Commercially Insured Population in the United States.
Cheng LI; Durden E; Limone B; Radbill L; Juneau PL; Spangler L; Mirza FM; Stolshek BS
J Manag Care Spec Pharm; 2015 Sep; 21(9):824-33, 833a. PubMed ID: 26308229
[TBL] [Abstract][Full Text] [Related]
19. The comparison of alendronate and raloxifene after denosumab (CARD) study: A comparative efficacy trial.
Ramchand SK; Tsai JN; Lee H; Sassana-Khadka G; Jordan M; Ryan S; Leder BZ
Osteoporos Int; 2024 Feb; 35(2):255-263. PubMed ID: 37798320
[TBL] [Abstract][Full Text] [Related]
20. Effects of denosumab on bone mineral density and bone turnover in postmenopausal women transitioning from alendronate therapy.
Kendler DL; Roux C; Benhamou CL; Brown JP; Lillestol M; Siddhanti S; Man HS; San Martin J; Bone HG
J Bone Miner Res; 2010 Jan; 25(1):72-81. PubMed ID: 19594293
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
